Get these analyses to your inbox — https://axialfc.substack.com/ This is a newsletter for new financing events with some simple analysis. More well thought out work can be found at — https://axial.substack.com/ I figured that there is a diversity across desire for frequency of emails.
Axial invests and partners in early-stage life sciences companies. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company — info@axialsprawl.com
Life Sciences Financings and Commentary #4 — April 18, 2020 — April 24, 2020
Financings
Number of deals: 16 & Total capital invested: $528M
- Accent Therapeutics raised $63M led by EcoR1 Capital to develop new medicines for cancer pursuing the epitranscriptome — the “collection of RNA-modifying proteins (RMPs) that control many aspects of RNA biology.”
- Affinivax raised $120M led by Viking Global to develop vaccines covering covers 24 strains of pneumococcus — https://www.fiercebiotech.com/biotech/affinivax-banks-120m-to-push-vaccines-against-hospital-associated-superbugs
